Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)

Management noted that the acquisition aligns with the company’s strategy by expanding its beingness successful big immunization done Dynavax’s candidates. Moreover, HEPLISAV-B is the lone two-dose big hepatitis B vaccine approved successful the US. The cause is administered successful 2 monthly doses for faster extortion compared to three-dose competitors implicit six months.

The woody is valued astatine $15.50 per stock successful cash, which totals to astir $2.2 cardinal successful equity value. Moreover, the woody has already been unanimously approved by the Dynavax committee of directors and is expected to adjacent successful the archetypal 4th of 2026. Management noted that this woody volition not interaction Sanofi’s (NASDAQ:SNY) fiscal guidance for 2025.

That said, Wall Street has a affirmative outlook connected the stock, with analysts’ 12 period terms people reflecting much than 26% upside from the existent level. Recently, connected December 17, Steve Scala from TD Cowen reiterated a Hold standing connected the banal with a terms people of $57.

Sanofi (NASDAQ:SNY) is simply a planetary healthcare institution engaged successful the research, development, manufacture, and selling of therapeutic solutions crossed pharmaceuticals, vaccines, and user healthcare.

While we admit the imaginable of SNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.